One Sentence Summary: 25 Single-cell analysis revealed that IL-2 mutein treatment expanded multiple sub-states of Tregs with a highly suppressive function in mice.
Abstract:
The therapeutic expansion of Foxp3 + regulatory T cells (Tregs) shows promise for treating autoimmune and inflammatory disorders. Yet, how this treatment affects the heterogeneity and function of Tregs is not clear. Using single-cell RNA-seq analysis, we characterized 31, 908 Tregs from the mice treated with a half-life extended mutant form of murine IL-2 (IL-2 mutein,
Main Text Introduction
Foxp3 + regulatory T cells (Tregs) play a fundamental role in immunosuppression and immune tolerance, and there is great interest in harnessing Treg populations to treat autoimmune and inflammatory disorders. The differential expression of transcription factors, costimulatory 5 receptors, chemokine receptors, and secreted effectors in quiescent and activated Tregs suggests that the heterogeneous Treg states exist and perform distinct functions (1) (2) (3) . Moreover, nonlymphoid tissue Tregs acquire unique phenotypes different from lymphoid-tissue Tregs, suggesting that the anatomical location of Tregs contributes to their heterogeneity (4, 5) .
Recently, low-dose Interleukin-2 (IL-2) therapies have been tested to induce tolerance in 10 patients with autoimmunity and inflammatory disorders (6) (7) (8) (9) (10) (11) . Although the low-dose IL-2 therapies expand Tregs, their effect has been limited by concomitant increases in conventional effector T cells and natural killer cells. To improve selectivity and pharmacokinetics of low-dose IL-2, alternative modalities have been considered(12). However, it is not clear how IL-2-based therapies impact Treg heterogeneity in diverse tissues. Since the goal of Treg-targeted therapies 15 is to expand Treg-mediated tolerance at the proper anatomical locations, it is critical to understand how IL-2-mediated expansion impacts the phenotypic and functional heterogeneity of Tregs in lymphoid and non-lymphoid tissues.
Thymic-derived Foxp3+ Tregs undergo T cell receptor (TCR) dependent antigen priming and activation-induced expansion in lymphoid organs followed by extravasation into peripheral 20 tissues, where they acquire tissue-specific tolerogenic phenotypes. Given the complex migratory patterns of Tregs, it is unclear how IL-2-mediated therapy affects Tregs within and across tissues. TCR-sequencing combined with single-cell profiling provides an opportunity to measure IL-2-induced Treg differentiation and movement by tracing the transcriptional conversions and trafficking patterns of clonal lineages.
To better understand the impact of the IL-2-mediated Treg expansion therapy on Foxp3 + Treg heterogeneity in lymphoid and non-lymphoid tissues, we profiled mouse spleen, lung and gut Tregs using single-cell RNA-seq (scRNA-seq) with TCR-sequencing under murine 5 IL-2 mutein (IL-2M) stimulation or homeostatic (mouse IgG Fc isotype control-treated) conditions. Comparison of resting, primed/activated, and activated Treg states from different tissues revealed unique gene signatures shared between spleen and lung Tregs, as well as distinct activation profiles of gut Tregs. Administration of murine IL-2M dramatically changed the landscape of Tregs in the spleen and the lung, while maintaining tissue-specific identity in the 10 gut. TCR-profiling coupled with scRNA-seq revealed gene expression dynamics governing Treg differentiation after IL-2M treatment and uncovered a migratory axis across tissues.
Additionally, we identified a population of activated Tnfrsf9 + Il1rl1 + Tregs in mice that expands following IL-2M and suppresses convention T cells robustly in vitro. Overall, our experiments provide new insights into the relationships between Foxp3 + Treg activation states and their 15 phenotypic heterogeneity in different tissues during homeostasis and after murine IL-2M stimulation. 20 To determine the specific role of mouse IL-2 in Foxp3 + Tregs in mice, a half-life extended mutant form of murine IL-2 (IL-2 mutein, IL-2M) was generated as an Fc fusion protein. Administration of murine IL-2M to C57BL/6 mice with different doses revealed that 0.33 mg/kg of murine IL-2M specifically increased Foxp3 + Tregs in the spleen, lymph nodes, blood and lung, while it did not affect CD25 ─ Foxp3 ─ T conventional cells (Tconv) (Fig. 1A, Fig. S1A-D). Murine IL-2M increased percentages and cell numbers of CD25 + Foxp3 ─ activated CD4 T cells slightly at a higher dose ( Fig. S1A) , likely due to the presence of high affinity IL2R
Results

A half-life extended mutant form of murine IL2 expands CD25 + Foxp3 + Tregs in vivo.
(IL2R in CD25 expressing cells (13, 14) . Expansion of CD25 + Foxp3 + Tregs by IL-2M was comparable to IL-2/anti-IL2 antibody (JES6-1) conjugate (IL-2C) which was previously reported 5 to expand Tregs (15) (Fig. S2C ), but IL-2C increased more CD25 + Foxp3 ─ activated CD4 T cells compared with IL-2M ( Fig. S2D) .
In vivo expanded Tregs by IL-2M displayed superiority in suppressing the proliferation of Th1 effector cells ( Fig. 1B) as well as generation of IFN from Th1 effector cells in vitro compared with Foxp3 + Tregs isolated from spleens of PBS-treated mice (Fig. 1C ). While these 10 results revealed that highly suppressive Tregs expanded after IL-2M treatment in vivo, it was not clear how IL-2M impacted on heterogeneity of Tregs towards functional suppression in lymphoid and non-lymphoid tissues. We therefore sought to profile the molecular phenotypes expressed by Tregs to understand how IL-2M elevates Treg expansion and suppression in mice. 15 
Isolation and scRNA-seq of Tregs from spleen, lung and gut
The therapeutic success of Treg expansion depends on the efficacy of Treg immunosuppression at specific anatomical sites. To characterize the heterogeneity of Tregs and assess how IL-2M reshapes this diversity, we performed scRNA-seq on Foxp3 + Tregs from multiple tissues at steady-state and after IL-2M treatment. CD4 + eGFP + single cells were sorted 20 from the spleen, lung, and gut of Foxp3-eGFP mice and single cell libraries were prepared using the 10x Chromium platform ( Fig. 2A) . After filtering and cross-sample normalization using Seurat(16), we recovered 17,097 spleen Tregs, 10,353 lung Tregs, and 4,458 gut Tregs across three replicates with roughly equivalent Tregs in mouse IgG Fc isotype control (Iso)-and IL-2Mtreated conditions (16,152 and 15,756 cells, respectively). Single-cell molecule and gene recovery rates showed good concordance between Iso-and IL-2M-treated cells ( Fig. S3A-B ). To establish that we had accurately sorted and sequenced Tregs, we additionally performed scRNAseq on CD4 conventional T cells sorted using FACS. Comparison of Tregs and Tconvs 5 confirmed that Tregs and Tconvs expressed distinct transcriptional profiles and clustered into distinct groups (Fig. S4A ). Additionally, Tregs expressed higher transcript levels of established Treg genes such as Foxp3, Il2ra, Ctla4, Ikzf2, and Nrp1, while both cell types expressed similar levels of Cd4 (Fig. S4 , B and C).
10
Molecular characterization of resting, primed, and activated Treg cell states across all tissues.
Previous scRNA-seq profiling efforts have identified resting, early-activated (primed/activated), and terminal effector states along the Treg cell differentiation continuum (4, 17) , (18) (19) (20) . We sought to organize all Tregs from our dataset into different cellular states to generate a single-cell Treg classification schema, which could then define cellular variation 15 across tissues and after IL-2M stimulation. To do this, we first impartially defined cell states using unsupervised clustering, then identified highly representative signature genes from each cell state to anchor our cell state assignments in the context of known Treg biology.
Cell clustering using the graph-based Louvain algorithm from Seurat(21) identified ten Treg states that were differentially distributed in isotype control (Iso)-and IL-2M-treated mice 20 ( Fig. 2B ). These clusters were evenly represented in all replicates, indicating that they represent biological heterogeneity and not batch-specific processing artifacts (Fig. S5, A and B ).
Signature genes were then defined for each cell state to understand transcriptional differences between Treg populations (see Methods) ( Fig. 2C, Fig. S6A ). Cell states identified by clustering could be grouped into resting, primed/activated, and activated Treg populations based on known lymphoid-associated and activated gene expression. Resting Tregs (C1) have high expression of lymphoid-tissue homing receptors (Ccr7, S1pr1, Sell) and Treg-establishing 5 transcriptional regulators (Lef1 (22) , Satb1(23) and Klf2 (24) ) and low activation marker expression (Ctla4, Icos, Tnfrsf1b, Tnfrsf4) ( Fig. 2D, Fig. S7A ), suggesting that they either have not yet undergone TCR-mediated activation or have a central memory-like phenotype.
Two primed/activated Treg states (C2 and C9), express intermediate levels of both resting and activation gene sets, suggesting they may be transitioning toward an activated 10 phenotype (Fig. 2D, Fig. S7A ). In support of this observation, primed/activated Tregs are distinguishable from C1 resting Tregs with higher expression of Treg-specific genes that stabilize inhibitory activity of Treg (C2: Ikzf2 (25) and S100 family proteins) or inflammatory response mediators (C9: Stat1, Cxcl10, and interferon-response genes) ( Fig. S7 , B and C). Both C2 and C9 have high Ms4a4b expression ( Fig. S7D ), which modulates activation by regulating 15 proliferation and augmenting co-stimulation through GITR (26, 27) . Furthermore, C2-and C9-Tregs could be distinguished from each other, as C2-Tregs express more Nrp1 (which is expressed highly in natural Tregs(28) and promotes Treg survival by interacting with Sema4a on Tconv cells(29)), while C9-Tregs uniquely express interferon-response genes(30) (Bst2, Tgtp2, Ifit1, and Isg15) (Fig. S8, A and B ). 20 Six Treg clusters (C3-C5, C7, C8, and C10) showed an activated phenotype with the lowest expression of lymphoid-tissue homing markers and highest expression of activation genes ( Fig. 2D ). While activated cell states express high Tnfrsf9 (encoding for costimulatory activator 4-1BB), each population also expresses distinct genes ( Fig. 2E ). Differential gene expression of these activated clusters compared with C1-resting cluster or C2-primed/activated cluster or each other was shown ( Fig. S6 , B to E, Fig. S9 , and Fig. S10 ). Both C4 and C8 Tregs express high Il1rl1 (ST2) compared to all other states (2, (31) (32) (33) (34) (35) , while they differentially express T-cell activation regulators and effector molecules (C4: Ass1, Klrg1, Gzmb, and Tagln2 vs. C8: Itgb7, 5 Cd52, and GITR) ( Fig. 2E, Fig. S6 , B to E, Fig. S9B and Fig. S10B ). Similarly, C4 and C8 Tregs expresses high CXCR3, a chemokine receptor regulated by T-bet and associated with tissue Tregs that suppress Th1 responses(36) ( Fig. 2E ). On the other hand, C3 Tregs express genes required for follicular regulatory phenotype (C3: Maf (37) ) and genes that promote Treg survival and persistence (C3: Nr4a2, Cst7) ( Fig. 2E and 3C, Fig. S6B and S9A), while C5 Tregs 10 express effectors that promotes suppression (C5: Il10(38), Gzma (39) and Gzmb (40, 41) ) or tissue protection (C5: Areg(42)) ( Fig. 2E and 3C, Fig. S6 B to E, and Fig. S9C ). C7 Tregs is a small population that expresses stress response genes (Hspa1a and Hspa1b). C10 Tregs is a small population as well, expressing genes associated with NK cells (NKG7, CCl5, CXCR6, Gzmb) and cytokine (Ifng), which is expressed in ex-Tregs(43) ( Fig. S10 ). 15 In addition, we identified one proliferative cell state (C6) (Mki67 and Top2a) that coexpresses activation markers ( Fig. S9D ).
Analysis of Treg clusters at steady state identified tissue adaptations of Tregs.
We next sought to characterize the Treg landscape in the spleen, lung and gut from mice 20 treated with isotype control using the classification of Treg states described in Figure 2 as a reference criterion. At the tissue level, the spleen and lung share a >40% frequency of C1-resting and minor frequencies of primed/activated and activated Tregs. Conversely, >80% of gut Tregs are activated and the majority are C5-Tregs ( Fig. 3, A and B ). While lymphoid organs, such as the spleen, are known to contain large reservoirs of resting Tregs that can be recruited during immune challenge, the prominence of resting Tregs in the lung is noteworthy and suggests that the lung plays an active role in steady-state immune surveillance.
Activated states of Tregs differ substantially between the tissues, indicative of tissue 5 adaptations acquired by Tregs (Fig. 3A) . The spleen in unperturbed state uniquely contained over 30% C3-Nr4a2 hi activated Tregs, which express differentiation-promoting transcription factor Nr4a2(44). In contrast, the lung did not contain the C3-Nr4a2 hi Tregs as a main activation state.
Rather, the lung contains the C4-Ass1 hi and C8-Itgb7 hi activated clusters and C6-Stmn1 hi proliferative cluster. Comparison of C3 and C4 revealed that C3 cluster differentially express 10 TBC1D4, a transcription factor highly expressed in follicular regulatory Tregs, suggesting C3-Nr4a2 + activated Tregs include Tfr in the spleen (Fig. 3E ). The coexpression of immunomodulatory genes (Cst7, Izumo1r (45) , Nt5e(CD73) (46) ) and a reduced activation The C5-IL10 hi Tregs uniquely express effectors such as IL10 and tissue repairing Areg (47) ( Fig.   2E , Fig. S9C ) and pro-inflammatory transcriptional regulator Rora (2) and elevated levels of gut-homing chemokine receptor Ccr9 (48) . The C7-Dnajb1 hi activated Tregs express early response inflammatory (Dnajb1 (49) , Hspa1a (50, 51) , Tagap (52) , interferon-response-related) genes, some of which are associated with enhanced Treg function and autoimmunity ( Fig. S10A ). Given that cells in the gut regularly encounter diverse commensal microbes and food antigens, these Tregs may actively promote tolerance even during steady state conditions. 5
Reorganization of Treg landscape in multiple tissues after treatment with murine IL-2 mutein
We demonstrated the expansion of Tregs after murine IL-2M in vivo ( Fig.1, Fig. S1 , and and spleen Tregs shared most of the genes following IL-2M treatment ( Fig. S11A ), but they were 15 distinct when compared with gut Tregs (Fig. S11 , B and C). In the spleen, lung, and gut, C2primed Tregs and C4-activated Tregs all displayed an over four-fold increase in all animals ( Fig.   4C ). This expansion of C2-and C4-Tregs in the spleen and lung established these two states as the most prominent Treg populations after IL-2M stimulation, coinciding with a drastic reduction in C1-resting Tregs in both tissues and in C3-activated Tregs in the spleen. A two-fold increase 20 was also observed in C8-activated Tregs in the spleen and lungs. The selective expansion of C4and C8-Tregs, which both co-express Tnfrsf9 and Il1rl1, suggests that IL-2M may skew expansion in eligible tissues toward specific activation phenotypes. Despite an increase in C2, C4 and C6 Treg states after IL-2M treatment, gut Tregs still maintained C5-activated Tregs as the most prominent cell state ( Fig. 4 , B and C).
IL-2 mutein skews clonal Treg expansion toward specific activation states
During development in the thymus, each T cell generates a unique TCR and - 5 rearrangement (or clonotype), which predicates antigen specificity and influences Treg fate. This clonotype is retained in cells that descend from a common progenitor T cell, enabling characterization of Tregs that share a developmental lineage. Since we observed an expansion in Tregs (1) toward distinct cell states (C2, C4, and C6) in all three tissues, (2) toward the C8 state in the spleen and lungs, and (3) away from the C3 state in the spleen, we analyzed TCR 10 information combined with Treg cell state classifications from single cells to elucidate whether these cell states expand independently of one another or whether they are developmentally related.
From the 3,600 sequenced single-cell transcriptomes where TCR and TCR were also recovered (see Methods), 3,405 unique Treg clonotypes (1,428 in Iso-and 1,977 in IL-2M- 15 treated conditions) were identified. Of these clonotypes, 119 clonal families (i.e. clonotypes that were shared by at least two Tregs) consisting of 314 total Tregs were identified. Among the 119 clonal families, 67 clonal families of Tregs existed in different phenotypically distinct activated states (e.g. C3 and C4) or in primed/activated and activated states (e.g. C2 and C4), at both steady state and after IL-2M stimulation ( Fig. S12 ), revealing that different Treg cell states can 20 be derived from the same parental Treg. The identification of transcriptional diversity among Tregs from the same clonal family was an interesting result, since we also find that pairs of T cells belonging to the same clonotype tend to be transcriptionally correlated than randomly sampled pairs of Tregs at the population level, although this was a modest effect (20) (Fig. S13 ).
Clonal family membership also revealed evidence of Treg migratory patterns between tissues, since we observed that Tregs of the same clonotype spanned the spleen, lung and gut ( Fig. S12 ).
Taken together, we interpret these findings as such that, although the TCR responses may generally influence the transcription of Tregs toward a programmed transcriptional fate, clonally-5 related Tregs still can differentiate into multiple cell states depending on the tissue. We next characterized cell state classifications of clonotype pairs to identify cell states that may be developmentally linked (which we refer to as "cell state axes"). At steady state, no cell state axis comprised more than 1% of all clonotypes, since the majority of clonotypes (95.6%) did not belong to a clonal family ( 15 multiple clonotypic pairs were observed in the C4-Tregs, including proliferation-dependent C4-C4 (3.9%) and C4-C6 (2.7%) clonotype pairs, as well as C2-C4 (1.0%) and C3-C4 (1.1%) pairs, revealing that C2, C3, and C4 are developmentally linked (Fig. 5, A and B ). C4 also shared clonotypes with activated states C7 and C8, albeit at a lower frequency of 0.5% and 0.2%, respectively. 20 Given that IL-2M increases clonal Treg expansion, we also examined how IL-2M influences the localization of CF Tregs by comparing the frequency of CF Tregs that were shared across tissues versus within the same tissue. While the percentage of inter-tissue CFs remained the same in both Isotype and IL-2M conditions (3.9% versus 4.2%, respectively), the percentage of CFs found only in one tissue was nearly doubled (3.0% versus 5.8%, respectively). Although we cannot ascertain whether in situ expansion or migration from other tissues is responsible for this phenomenon, these results indicate that CF Tregs after IL-2M-induced clonal expansion are more frequently observed in the same tissue than across multiple tissues. Interestingly, shared TCR clones were also found in multiple and distinct cell states, providing us with a molecular snapshot of the transcriptional changes following IL-2M stimulation.
C4 and C8 Tregs expand after IL-2M stimulation through C2/C3 intermediate states
Cell clustering of Treg single-cell data generated a universal criterion of Treg states to detect variation in the molecular profiles of Tregs across tissues and treatment. Many of the marker genes, which have previously been studied in Tregs as a bulk population, allowed us to 5 infer functions associated with Treg sub-populations. As a result, cell clustering identified ten clusters with distinct combinatorial transcriptional profiles, which could be more generally grouped into one resting, two primed-activated, one proliferative, and six activated cell subsets.
The signature genes that classified these populations align well with previous Treg-focused scRNA-seq studies (4, 20) . For example, S1pr1, Ccr7, Sell, and Satb1 identify resting Tregs, 10 while suppressive Tregs express genes such as Il10, Rora, and Tnfrsf9. Our study also identified primed-activated populations, and showed that they share a developmental lineage, express intermediate levels of resting and activated genes, and can give rise to suppressive (C5) or terminally differentiated (C4/C8) effector Tregs. As our TCR analyses suggest, we believe these clusters should be considered as activation states along the Treg differentiation continuum and 15 not Treg subsets that arise independently.
The similarities in single cell profiles between the spleen and lung versus the gut at steady state suggest that the spleen and lung in healthy mice possess a large proportion of resting-Tregs (C1-resting Tregs) that serve as a reservoir of Tregs in preparation for potential and C8, express high Il1rl1 (ST2), which is the receptor for tissue alarmin IL-33 (33) . ST2 + Tregs have been previously shown to prevent excessive tissue damage in organs such as the skin, liver, 20 and gut (2, 76, 77 suppressive Tregs, which mediate potent immunosuppression in these tissues.
We provide evidence using TCR analyses and trajectory analyses to suggest that C4 and C8 Tregs differentiate from C2/C3 primed/activated states. TCR analyses identify that C2, C3, C4, and C8 Tregs in the spleen and lung share clonotypes, demonstrating that they can all derive from a common progenitor. Cells from these populations that share the same clonotype are also 15 present across the spleen and the lung, revealing an immune trafficking axis that exists between the two tissues. Using trajectory analysis to order cells along a differentiation continuum, we
show that C2 and C3 Tregs contain cells throughout the trajectory manifold, suggesting these sub-states are transitional state between resting and further differentiated or activated Treg states.
C4/C8 Tregs, on the other hand, are mostly present on one of the termini on the trajectory 20 manifold. Taken together with the shared clonotype information, this suggests that IL-2Mexpanded C4 and C8 populations come from C2 and C3 populations. The ordering of identified cluster-specific marker genes correlates with classical genes known to identify resting (i.e. S1pr1
and Ccr7) and activated Tregs (i.e. Gzmb, Klrg1, and Icos), suggesting that the trajectory manifold recapitulates patterns of Treg differentiation. Trajectory analysis also identifies a bifurcation in Treg differentiation after IL-2M treatment, which either differentiate into suppressive Il10 + Rora + C5 Tregs, which are most prevalent in the gut, or into C4/C8 Tregs that are prominent in the spleen and lungs. 5 In this study, we characterize Tregs in the spleen, lung, and gut using scRNA-seq and analyze how the Treg landscape in these tissues is influenced by IL-2M stimulation. We identified an immune axis of clonal TCRs between the spleen and the lung and found an activated, Tnfrsf9 + Il1rl1 + Treg populations that expand highly upon IL-2M stimulation.
Supporting analyses indicate that this population differentiates through multiple primed and 
Materials and Methods
Mice and IL-2 mutein treatment
All experimental studies were conducted under protocols approved by the Institutional Animal For scRNA-seq experiment, mice were administered with murine IL-2 mutein (0.33 mg/kg) or 20 mouse IgG Fc isotype control (Iso) by intraperitoneal (IP) injection and were sacrificed 4 days after murine IL-2M administration. `
IL-2/anti-IL2 antibody complex (IL-2C)
IL-2 complex (IL-2C) was prepared as described (79) (2) we reasoned that the developmental trajectory should be preserved across treatment condition. We removed cells (i.e. C6 Tregs) whose primary marker genes were driven by proliferative status and not by their relative status along Treg-specific differentiation, although an independent analysis including these cells revealed that they are dispersed evenly throughout the trajectory manifold, which is expected since both resting and activated cell states 5 are capable of proliferation. The gene list used for pseudotime analysis was filtered to include genes expressed in greater than 10% of all cells in the data (5,311 genes). We then used Monocle DDRTree to perform dimension reduction and manifold constructing, representing the trajectory of Treg differentiation. Cells were then ordered along the manifold. 
